Kane Biotech Inc Ord (KNBIF) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Parties will be in a listen-only mode. Following the presentation, the conference call will be open to questions. If you have a question, please press star, then 1-1 on your touchtone phone. If you would like to withdraw your question, please press star, 1-1 again. This conference is being recorded today, August 29th, 2024. I would now like to turn the conference over to Ray DuPois, Kean Biotech's Chief Financial Officer. Please go ahead. Thank you, Operator. Good afternoon and welcome everyone to CAEN Biotech's second quarter 2024 earnings conference call. We are delighted to have you join us today. This call will cover CAEN's financial and operating results, along with a discussion of some of our recent highlights and goals for the range of 2024 and beyond. Following our prepared remarks, we will open the conference call to a question and answer session. Our call today will be led by CAEN's Chief Executive Officer, Mark Edwards. Before we begin our formal remarks, I would like to remind everyone that some of the statements on this conference call contain certain forward-looking information and statements within the meaning of securities law, which may not be based on historical fact, including without limitation statements containing the words believes, should, may, plan, will, estimate, predict, continue, anticipates, potential, intends, expects, or other similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the company's stage of development, lack of product revenues, additional...